3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 1
2
Phase 2
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Neoplasm, Residual
1
Leukemia, Myeloid, Acute
1
Interventions
pembrolizumab
242
Carboplatin
137
Nivolumab
132
Gemcitabine
127
Paclitaxel
116
Cisplatin
105
Cyclophosphamide
97
Bevacizumab
93
Dexamethasone
78
Injections
75
Pemetrexed
71
Docetaxel
71
Fluorouracil
68
Capecitabine
65
Rituximab
61
Cetuximab
61
atezolizumab
59
130-nm albumin-bound paclitaxel
59
Oxaliplatin
58
Leucovorin
57
Ipilimumab
54
fludarabine
50
Lenalidomide
47
Azacitidine
40
Irinotecan
39
venetoclax
38
Fulvestrant
38
Albumin-Bound Paclitaxel
36
Prednisone
35
Trastuzumab
34
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
INDUSTRY
×
Anthracyclines
×
Clear all
NCT03760445
2020-01-09
HDM201 Added to CT in R/R or Newly Diagnosed AML
Novartis
Phase 1/2
Withdrawn